Inovio Pharmaceuticals (INO) Income from Continuing Operations (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Income from Continuing Operations of 23642400.0 for Q1 2026, down 38.85% sequentially from 17027264.0 in Q4 2025, and up 37.64% YoY from 17176637.09 in Q1 2025.
Inovio Pharmaceuticals (INO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 23642400.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 37.64% year-over-year to 23642400.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84412952.0 (up 27.78% YoY) and the FY2025 annual result came in at 462877944.0, down 1.32% from the prior year.
- Income from Continuing Operations eased to 23642400.0 in Q1 2026 per INO's latest filing, from 17027264.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 17027264.0 in Q4 2025 and troughed at 108497311.0 in Q2 2022.
- A 5-year average of 38007637.82 and a median of 33210235.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 42.51% in 2022, then surged 67.25% in 2023.
- Over 5 years, Income from Continuing Operations stood at 54463139.0 in 2022, then jumped by 54.09% to 25003638.0 in 2023, then grew by 21.94% to 19516807.0 in 2024, then increased by 12.76% to 17027264.0 in 2025, then slumped by 38.85% to 23642400.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 23642400.0, 17027264.0, and 20658347.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | -18.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.51 Mn |
| Mar 31, 2026 | -23.64 Mn |
| Dec 31, 2025 | -17.03 Mn |
| Sep 30, 2025 | -20.66 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -37.91 Mn |
| Dec 31, 2024 | -19.52 Mn |
| Sep 30, 2024 | -26.24 Mn |
| Jun 30, 2024 | -33.21 Mn |
| Mar 31, 2024 | -32.06 Mn |
| Dec 31, 2023 | -25.00 Mn |
| Sep 30, 2023 | -33.93 Mn |
| Jun 30, 2023 | -35.53 Mn |
| Mar 31, 2023 | -40.65 Mn |
| Dec 31, 2022 | -54.46 Mn |
| Sep 30, 2022 | -37.78 Mn |
| Jun 30, 2022 | -108.50 Mn |
| Mar 31, 2022 | -76.91 Mn |
| Dec 31, 2021 | -106.95 Mn |
| Sep 30, 2021 | -60.17 Mn |